Puration, Kaly Confirm M&A Deal, Say Research Underway On CBD, Coronavirus Symptoms

 

March 4, 2020 -- InvestorsHub NewsWire -- via Jose Rodrigo , Benzinga Staff Writer 
March 03, 2020

Puration Inc PURA and Kali-Extracts KALY said Monday that a planned acquisition by Pura of Kaly's CBD confections operations is underway. 

Kaly is focusing its business on cannabis extract biopharmaceuticals, and its leading research has been on the treatment of respiratory conditions, the companies said. 

Kaly has filed a new patent application on its CBD formulation for the symptoms of COPD and similar respiratory conditions, the companies said. The company has also filed for a trademark on the name RespRx as a brand of CBD for COPD symptoms and other conditions that cause respiratory inflammation. 

The company said it is evaluating its proprietary CBD extract formulation as a treatment for symptoms of coronavirus. 

See other recent BENZINGA articles on cannabis sector compaines including James E. Wagner Cultivation Corporation (OTC:JWCAF), and Tilray, Inc. (TLRY).

 

SOURCE: Jose Rodrigo, Benzinga Staff Writer

Puration (PK) (USOTC:PURA)
Historical Stock Chart
From Apr 2020 to May 2020 Click Here for more Puration (PK) Charts.
Puration (PK) (USOTC:PURA)
Historical Stock Chart
From May 2019 to May 2020 Click Here for more Puration (PK) Charts.